Double duty: Anti-HIV topical gel also protects against herpes virus

October 19, 2011 in HIV & AIDS

HIV infection is commonly associated with other sexual infections, such as herpes simplex virus (HSV). Infection with HSV facilitates the risk of HIV infection and negatively impacts the clinical course of HIV disease. Therefore, it would be highly beneficial to identify multi-faceted microbicide compounds that are efficient against HIV-1 and other sexually transmitted infections.

Now, a new study published by Cell Press in the October 20th issue of the journal explains why a change in the delivery method of an established anti-HIV drug results in dual protection against both HIV and HSV. The research is the result of an between Belgian, Italian and American laboratories; senior authors Prof. Jan Balzarini from the Rega Institute for Medical Research in Belgium, Prof. Carlo-Federico Perno from the University of Rome "Tor Vergata" in Italy and Dr. Leonid Margolis from the National Institute of Child Health and Human Development, Bethesda, MD, USA.

There has not been much success in generating new clinically useful microbicide compounds, so, recently, a substance called "tenofovir", which has been widely used in as an oral tablet, was formulated as a topical and tested in a large study of nearly 900 South African women. Tenofovir works by inhibiting an enzyme that HIV needs to make copies of itself. Surprisingly, not only did the microbicide significantly reduce HIV-1 transmission, it also caused a dramatic reduction in the risk for infection with HSV.

The effect of tenofovir gel on HSV was unanticipated because the drug had previously shown very minimal activity against HSV. "We hypothesized that the discrepancy between the earlier reported lack of significant anti-HSV activity and the new data might be explained by the striking differences in drug concentrations between the oral tenofovir delivery system and topical application of the gel," explains Prof. Balzarini.

Prof. Balzarini and colleagues demonstrated in a variety of experimental models that when tenofovir was applied at concentrations similar to those obtained in the gel, the drug had a potent and direct anti-HSV activity. The researchers went on to unravel the molecular mechanism of the anti-HSV activity and found that, like the effect on HIV, tenofovir efficiently inhibits an enzyme needed for herpes viral replication.

Taken together, the results demonstrate that topical administration of tenofovir achieves drug concentrations that exert both anti-HIV and anti-HSV activity. "Our data and the therapeutic principles emerging from our study are important for the design of new drug formulations and administration protocols to develop and/or optimize future microbicide trials," concludes Dr. Margolis.

Provided by Cell Press search and more info website

3.7 /5 (3 votes)  

Rank 3.7 /5 (3 votes)
Relevant PhysicsForums posts

More news stories

'Gap' for HIV vaccine efforts after latest setback

The hunt for an HIV vaccine has gobbled up $8 billion in the past decade, and the failure of the most recent efficacy trial has delivered yet another setback to 26 years of efforts.

HIV & AIDS created 23 hours ago | popularity not rated yet | comments 0

AIDS science at 30: 'Cure' now part of lexicon

Big names in medicine are set to give an upbeat assessment of the war on AIDS on Tuesday, 30 years after French researchers identified the virus that causes the disease.

HIV & AIDS created May 18, 2013 | popularity 5 / 5 (2) | comments 0

Peer-referral programs can increase HIV-testing in emergency departments

Researchers at the University of Cincinnati (UC) have found that incorporating a peer-referral program for HIV testing into emergency departments can reach new groups of high-risk patients and brings more patients into the ...

HIV & AIDS created May 17, 2013 | popularity not rated yet | comments 0

HIV no barrier to getting liver transplant, study finds

(HealthDay)—Liver transplants to treat a common type of liver cancer are a viable option for people infected with HIV, according to new research.

HIV & AIDS created May 17, 2013 | popularity not rated yet | comments 0

Twin epidemics: HIV and Hepatitis C in the urban Northeast

A new Yale study looks at the scope and consequences of a burgeoning health problem in the cities of the U.S. Northeast: concurrent infection with both HIV and Hepatitis C (HCV). The study appears online ...

HIV & AIDS created May 17, 2013 | popularity not rated yet | comments 0


Lymphatic fluid takes detour

When tumours metastasise, they can block lymphatic vessels, as researchers from ETH Zurich have discovered using a new method. The lymphatic fluid subsequently has to find a new path through the tissue. Such ...

Research uncovers a potential role of two proteins in diabetes

(Medical Xpress)—Flinders University researchers are breaking new ground in a decade-long journey to pinpoint the function of two closely related proteins.

Vitamin D could provide new and effective treatments for asthma

(Medical Xpress)—Scientists at King's College London have discovered that Vitamin D has the potential to significantly reduce the symptoms of asthma. The study, led by Professor Catherine Hawrylowicz from ...

Rethinking treatment goals improves results for 'untreatable' anorexics

(Medical Xpress)—Patients with the most severe and dangerous form of chronic anorexia are more likely to make a significant improvement towards recovery and stay in therapy if traditional psychological treatments are re-focused ...

Discovery of novel medicine for treatment of chronic wounds

Every 20 seconds, a limb is lost as a consequence of diabetic foot ulcer that does not heal. To date, medical solutions that can change this situation are very limited. In his doctoral thesis Yue Shen from the Industrial ...

Rise in type 2 diabetes amongst young

The number of young people diagnosed with type 2 diabetes has seen the sharpest rise over the last twenty years compared to a background of a general increase across the board, new University research has ...